Dose-dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects.
In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. The present study examined the effects following i.v. administration of placebo and DMI (5, 15, 25, 50 and 75 mg) on GH, PRL and cortisol secretion in male subjects (n = 6). This primarily noradrenergic and secondarily serotonergic reuptake-inhibiting substance was found to stimulate the secretion of GH, PRL and cortisol in a dose-dependent manner. Compared to placebo, significant increases occurred in GH (p less than 0.05) and in PRL (p less than 0.05) from a dose of DMI 25 mg on, and in cortisol (p less than 0.05) from 15 mg on. The results indicate that, in addition to the dose, the method of administration influenced the effects of DMI on the three hormones.
D000293:Adolescent; D000302:Adrenal Cortex / Q000378:metabolism*; D000328:Adult; D003891:Desipramine / Q000494:pharmacology*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism
D012701:Serotonin; D011388:Prolactin; D013006:Growth Hormone; D003891:Desipramine; D006854:Hydrocortisone; D009638:Norepinephrine